Table S12. Differentially expressed genes (DEGs) in brain tumor-associated immune cells at 7d, under TMZ and TAT-Cx43 peptide treatments, shown in Figure 7C and Suppl. 6C.
Therapeutic targeting of the CD47-SIRPα axis has emerged as a pivotal strategy for enhancing phagocytic clearance of tumor cells and overcoming immune evasion in solid malignancies, yet clinical outco
Adaptive immunity is a targeted immune response that enables the body to identify and eliminate foreign pathogens, playing a critical role in the anti-tumor immune response. Tumor cell expression of a
